The innate immune system plays an important role in host defense. Over 15 years ago, we changed the paradigm of the ischemia/reperfusion injury field by identifying mannose binding lectin (MBL) as the initiator of complement activation in vitro and in vivo.
Since that time, we have found that MBL plays an important role in many other in vivo models of human disease. Dr. Stahl will discuss the role of MBL in myocardial ischemia, hyperglycemia, coagulation and hemolytic uremic syndrome using novel reagents and mice.